Huakang Biomedical Holdings Company Limited Stock

Equities

8622

KYG4644W1069

Medical Equipment, Supplies & Distribution

Market Closed - Hong Kong S.E. 04:09:00 2024-05-03 EDT 5-day change 1st Jan Change
0.098 HKD 0.00% Intraday chart for Huakang Biomedical Holdings Company Limited -2.97% -8.41%

Financials

Sales 2021 26.13M 3.61M 28.19M 4.94M Sales 2022 25.33M 3.5M 27.33M 4.79M Capitalization 67.72M 9.35M 73.07M 12.8M
Net income 2021 -4M -552K -4.32M -756K Net income 2022 -3M -414K -3.24M -567K EV / Sales 2021 1.78 x
Net cash position 2021 34.42M 4.75M 37.14M 6.51M Net cash position 2022 31.43M 4.34M 33.91M 5.94M EV / Sales 2022 1.43 x
P/E ratio 2021
-19.2 x
P/E ratio 2022
-21.5 x
Employees 96
Yield 2021 *
-
Yield 2022
-
Free-Float 56.96%
More Fundamentals * Assessed data
Dynamic Chart
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Huakang Biomedical Holdings Company Limited Provides Group Earnings Guidance for the Year Ended 31 December 2023 CI
An unknown buyer acquired 15.59% stake in Huakang Biomedical Holdings Company Limited from Ever Charming Inc for HKD 3.2 million. CI
Huakang Biomedical Holdings Company Limited Announces Change of Address of Head Office, Effect from 18 December 2023 CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Huakang Biomedical Holdings Company Limited Appoints Chow Ching Man as Independent Non-Executive Director Member of Audit Committee and Nomination Committee CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Huakang Biomedical Holdings Company Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2021 CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Huakang Biomedical Holdings Company Limited Provides Group Earnings Guidance for the Nine Months Ended September 30, 2021 CI
More news
1 week-2.97%
1 month-16.95%
3 months-22.22%
6 months-16.24%
Current year-8.41%
More quotes
1 week
0.10
Extreme 0.098
0.10
1 month
0.09
Extreme 0.091
0.13
Current year
0.09
Extreme 0.091
0.20
1 year
0.09
Extreme 0.091
0.22
3 years
0.09
Extreme 0.091
0.38
5 years
0.09
Extreme 0.091
0.38
10 years
0.09
Extreme 0.091
0.54
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 17-08-02
Director of Finance/CFO 52 17-08-02
Director/Board Member 38 18-12-31
Members of the board TitleAgeSince
Director of Finance/CFO 52 17-08-02
Director/Board Member 56 20-08-31
Director/Board Member 51 20-12-15
More insiders
Date Price Change Volume
24-05-03 0.098 0.00% 96 000
24-05-02 0.098 0.00% 48,000
24-04-30 0.098 -5.77% 304,000
24-04-29 0.104 +1.96% 576,000
24-04-26 0.102 +0.99% 216,000

Delayed Quote Hong Kong S.E., May 03, 2024 at 04:09 am

More quotes
Huakang Biomedical Holdings Co Ltd is an investment holding company mainly engaged in the production and sales of in-vitro diagnostic reagents. The Company operates its business through two segments. The Biological Reagents and Auxiliary Reproductive Supplies and Equipment segment is engaged in the research and development, production, marketing and sales of in-vitro diagnostic reagents, including male infertility in vitro diagnostic reagents, parasite series detection reagents and Epstein-Barr (EB) virus detection reagents. The Segment is also engaged in the manufacture and sale of auxiliary reproductive supplies and devices. The Healthcare Products and Supplements segment is engaged in the sales of health products and supplements.
More about the company

Annual profits - Rate of surprise